Semafore achieves preclinical milestone in cancer drug development
Specifically, SF2626 has demonstrated the ability to inhibit both Phosphoinositide-3-kinase (PI3K) and MEK, the key component of the RAS/RAF/MEK/ERK pathway. Both PI3K and MEK are frequently activated in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.